<DOC>
	<DOCNO>NCT00003015</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Randomized phase III trial compare effectiveness carboplatin plus vincristine treating child adolescent low grade glioma .</brief_summary>
	<brief_title>Carboplatin Plus Vincristine Treating Children Adolescents With Low Grade Glioma</brief_title>
	<detailed_description>OBJECTIVES : I . Develop standardized scheme therapy child adolescent low grade glioma . II . Determine effectiveness carboplatin vincristine treat child age less 5 year severe progressive symptom unequivocal image evidence tumor growth . OUTLINE : A complete resection tumor perform patient low grade glioma without neurofibromatosis type 1 . Surgery reconsider follow tumor relapse , progression , clinical deterioration . Every effort make obtain biopsy patient receive debulking surgery . Nonoperative patient postoperative patient candidate second surgery receive chemotherapy radiotherapy . Postoperative patient receive radiotherapy follow surgical wound heal within 28 day resection . Children le 5 year old receive chemotherapy first , radiotherapy tumor subsequently progress recurs . All patient receive radiotherapy , chemotherapy . The latter treatment conduct presence tumor progression . Chemotherapy give 2 part , first initial intensive phase ( phase 1 ) , late continuation phase ( phase 2 ) . In phase 1 , patient receive vincristine IV weekly 10 week carboplatin IV every 3 week . In phase 2 , patient receive vincristine IV carboplatin IV every 4 week total treatment time 52 week . Chemotherapy continue disease progression unacceptable toxicity . Patients receive radiotherapy daily 5 time week . Patients follow every 3 month 1 year , every 6 month 1 year , annually 3 year . PROJECTED ACCRUAL : A total 200 patient accrue study 5 year .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients without neurofibromatosis type 1 ( NF1 ) low grade glioma previously treat chemotherapy radiotherapy Tumor type consider : Low grade astrocytoma ( Kernohan grade 1/2 ) Oligodendroglioma Mixed oligoastrocytoma Ganglioglioma Patients NF1 hypothalamic/visual pathway glioma eligible without biopsy All CNS sit eligible , include biopsy proven low grade spinal tumor intrinsic brain stem tumors No malignant ( anaplastic ) glioma ( Kernohan grade 3/4 ) , glioblastoma multiforme , ependymal tumor PATIENT CHARACTERISTICS : Age : Under 16 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>January 2001</verification_date>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>untreated childhood visual pathway glioma</keyword>
	<keyword>untreated childhood cerebellar astrocytoma</keyword>
</DOC>